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Drug resistanceThe therapy of HIV patients is characterized by both
the high genomic diversity of the virus population
harbored by the patient and a substantial volume of
therapy options. The virus population is unique for each
patient and time point. The large number of therapy
options makes it difficult to select an optimal or near
optimal therapy, especially with therapy-experienced
patients. In the past decade, computer-based support
for therapy selection, which assesses the level of viral
resistance against drugs has become a mainstay for
HIV patients. We discuss the properties of available
systems and the perspectives of the field.
Introduction
HIV is one of the fastest evolving pathogens known, and as
yet, there is no vaccine for HIV. Because the patient, once
infected, cannot be cured of the virus, the goal of therapy is
to suppress virus replication, ease symptoms, and prolong
life. For this purpose, an arsenal of more than two dozen
different antiretroviral drugs has been developed in a short
period of time which is unparalleled for any other disease
today. Drugs inhibit a variety of steps in the viral replication
cycle. Although a certain drug therapy can be effective for
quite a long time, even several years, the virus eventually
manages to evolve into a resistant variant, leading to
therapy failure. When this happens, a new drug combination
has to be selected that effectively counters the resistance§ This is an open-access article distributed under the terms of the Creative Commons
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profile manifested by the virus population presently in the
patient. This is a difficult task to accomplish, but suitable
software can help to select efficient therapy options for
these patients. This review summarizes the history and
state-of-the-art of bioinformatics-based resistance analysis
and outlines perspectives into the future. For a previous
review of the field see [1].
History of analysis of HIV drug resistance
Generally, there are two approaches to resistance analysis of
HIV and other viruses. In phenotypic resistance assays viruses
are analyzed for their sensitivity against any one of an array
of drugs in vitro [2]. This laboratory procedure is highly infor-
mative in a research setting but is not amenable to clinical
routine testing, for several reasons: the assay is complex so that
it can only be performed in few highly specialized laboratories,
it is expensive and it is time-consuming (more than a week). An
alternative is genotypic resistance testing, which entails
sequencing the relevant parts of the virus genome and inter-
preting the sequence with respect to the resistance phenotype
of the virus [3]. Today, genotypic resistance testing is per-
formed routinely in developed countries as companion diag-
nostics in HIV therapy (Fig. 1).
The first approach to the analysis of genotypic resistance
data for HIV in history was performed using tables by expert
panels, who met regularly. They based their decisions on
evidence taken from literature, laboratory data and/oroi.org/10.1016/j.ddtec.2014.02.004 57
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Fig. 1. Workflow of current-day genotypic resistance analysis. The process begins by detecting the viral load (2) in a patient (1). In the case of anticipated
therapy change the viral genome is sequenced from the patient’s blood serum. (3). Interpretations of the viral genome sequence is effected either manually
using a mutation table (4a), or via a rules-based system (4b), or with a statistical model derived from clinical resistance data (4c). The interpretation results in
a resistance profile (5) that is qualitative in the first two cases and quantitative when using statistical models. The practicing physician uses this profile to
select a therapy (9). In doing so, he also takes additional information on the patient into account (patient history, habits, drug side effects, etc., 6). Therapy
prediction engines (7) can assist this process by a quantitative analysis that yields a list of therapies ranked by their likelihood of success (8).
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were and still are published at regular intervals [4].
The mutation table has boosted the efficacy of applied
antiretroviral therapies [5], but it suffers from two deficits:
The first is the limited information content of the table.
Specifically, a table cannot express interactions between
mutations; rather, each mutation acts on its own in confer-
ring the resistance of the virus to the drug, and neither
epistasis nor resensitization is considered. This limitation
has been overcome by the introduction of computerized
rules-based systems. These are, in effect, sets of rules that
can take more complex forms than the rules implicit in the
mutation tables. Take, for instance, the rule that the virus is
resistant to drug D if it has mutation M1 and does not have
mutation M2. This expresses the resensitization of the virus
by mutation M2 that has been rendered resistant to drug D by
mutation M1. In a rules-based system, also called a resistance
algorithm, the computer tests the relevant portion of a viral
genome against all rules in the set. There are several widely
employed systems, such as the ones offered by the Stanford
HIV Database [6], the Rega Institute [7], or the ANRS [8]. These
systems comprise the backbone of the computer-based inter-
pretation of genotypic resistance data as companion diagnos-
tics for present antiretroviral HIV therapy selection, today.
Both the mutation tables and the resistance algorithms
were designed manually on the basis of expert knowledge. In
the past decade, statistical analysis of clinical data – compris-
ing HIV resistance, drug therapy, and therapy follow-up – has
emerged as the third line of interpreting genotypic resistance
data. The geno2pheno server, which is available for free on
the Internet (http://www.genafor.org), is an example of such
a system [3,9]. The statistical approach is more systematic
than an approach that derives resistance rules manually.
Furthermore, the program calculates a more informative
notion of resistance by estimating the resistance factor, a
quantitative measure of the level of resistance as derived from
the phenotypic resistance assay. This is in contrast to the
classification of viruses by rules-based systems into the cate-
gories ‘resistant’, ‘susceptible’, and possibly ‘intermediate’.
There is evidence that the statistical approach provides
higher predictive performance than both mutation tables
and rules-based systems, as long as enough data are available
on HIV resistance for the respective drugs [10]. However,
prediction accuracy is not the only criterion for software that
interprets genotypic resistance data. Interpretability is an
important issue, because it is not sufficient just to present
the prediction result. In fact, the prediction system has to
make the prediction plausible to the medical user. If the
statistical prediction system lacks interpretability, users
may prefer the more interpretable rules-based systems, even
if they exhibit lower prediction accuracy. The virtual resis-
tance phenotype offered by the analysis method geno2phe-
no[resistance] is made interpretable by listing resistanceconferring mutations – those which are responsible for
increasing the level of resistance – and resensitizing muta-
tions – those which are responsible for reducing the resistance
level of the virus. This information has proven to be a valu-
able guideline for deciding on the best drug combination
therapies based on statistical resistance analysis [3]. Further-
more, annotations derived using the statistical approach are
used to supplement rules-based systems, as in the HIV-
GRADE interpretation system [11].
Two generations of prediction systems
Virtual phenotypes
We can distinguish two generations of prediction systems for
HIV resistance and the efficacy of antiretroviral therapy. The
first systems can be characterized as virtual phenotypes. In
general, a virtual phenotype is a computer-based procedure
that is designed to replace a laboratory assay. Virtual pheno-
types are useful in cases where the respective laboratory assay
can be performed in a research setting but not in clinical
routine. Phenotypic resistance analysis, as described above, is
one such type of assay. Genotypic resistance analysis with
computer-based interpretation of the viral sequence is, there-
fore, the virtual phenotype replacing the laboratory assay.
Virtual phenotypes are characterized by a simple laboratory
experiment that yields complex information on the patient –
usually a molecular fingerprint or sequence stretches of the
HIV genome – which is interpretable in terms of the relevant
disease phenotype. Both the resistance algorithms and the
bioinformatical systems for estimating resistance serve as
respective interpretation procedures.
Several virtual phenotypes are available for HIV resistance
analysis. Estimation of resistance against inhibitors of the
viral reverse transcriptase or protease is based on analysis of
the viral pol gene and are available both as rule sets ([6–8] for
latest references on system updates see [12,13,14]) and sta-
tistical prediction systems [9,15]. For viral resistance against
protease inhibitors, not only the pol gene coding for the
protease is important, but so also is the gag gene coding
for its viral substrate [16]. Rules-based analysis of this gene
is available as well. The use of such phenotypes for the inter-
pretation of genotypic resistance data has been shown to be
effective when considering anecdotal evidence and also in
several retrospective studies. As a consequence, the use of
virtual phenotypes is recommended by expert guidelines in
the US [17] and in Europe [18]. Resistance analysis for newer
drugs, for which fewer phenotypic resistance data are available
for training statistical models, is mostly performed with rules-
based systems. Box 1 describes a specially popular statistics-
based virtual phenotype for viral tropism, which is used as a
companion diagnostic for administering coreceptor blockers.
Most of the genotyping in clinical practice is still per-
formed using bulk Sanger sequencing. The sequencing out-
put is a consensus sequence, which summarily reflects thewww.drugdiscoverytoday.com 59
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Box 1. Genotypic testing of viral tropism
Viral tropism is the property of the virus that uses a specific cellular
coreceptor for cell entry. In vivo, one of two chemokine coreceptors can
be used by the virus CCR5 or CXCR4. In the early phase of infection,
almost exclusively those viruses are observed that use the CCR5
coreceptor, called R5-viruses. During the course of the infection, viruses
may emerge that are able to also use the CXCR4 coreceptor (dual-tropic
viruses) or CXCR4 exclusively (X4-viruses). This switch is associated
with the progress of the infection toward AIDS. It has been observed that
1% of the Caucasian population have a defunct CCR5 coreceptor. These
individuals have no apparent disease phenotype, but they are usually not
infected with HIV. This observation prompted the development of
CCR5-blockers. Since CCR5-blockers are only effective against a virus
that is not X4-capable, a viral tropism test has to be performed as a
companion diagnostic for administering CCR5-blockers [54]. Phenotypic
assays exist for this test [54–56] but are burdened with the same
problems as described for testing resistance against classical drugs. Viral
tropism is largely determined by a short (about 35 amino acids), highly
variable stretch (the V3 loop) of the viral surface protein gp120. Here,
there are no discernible effective rules such that the statistical approach
toward interpreting the genotypic data is the only viable one [57,58]. In
Europe, this approach, as implemented by the geno2pheno[coreceptor]
tool, is recommended by the relevant expert guidelines for HIV therapy
[23]. Versions of statistical coreceptor prediction based on more
advanced models have been published [22,59,60]. There is an ongoing
discussion about the relative worth of the different forms of tropism tests
[23,43,61].
Box 2. HIV – spearheading personalized medicine
With the advent of the first protease inhibitors and a growing number of
reverse transcriptase inhibitors in the mid-1990s, the HIV infection was
the first viral disease for which a substantial number of therapy options
became available [62]. This was a new situation in medicine, as complex
drug combinations were not applied against any other disease, with the
exception of the bacterial infection tuberculosis. However, because
tuberculosis is typically not chronic, the time interval for which medica-
tion is required is limited and bacterial resistance can be countered with
relatively simple and schematic tabular approaches to drug selection [63].
HIV, by contrast, is a chronic disease for which resistance patterns
become more and more complex as the patient becomes more therapy-
experienced.
Hence, HIV therapy exhibits all the characteristics that we envision for
many other diseases in the future: (1) The characterization of the disease
state is based on detailed molecular profiling of a patient, in this case, the
genomes of the viral population harbored by a patient. This character-
ization is unique for each patient and time point, as we do not expect the
exact same viral population to recur in different patients at different
times, at least not in therapy-experienced patients. (2) There is a large
number of therapy options – running into the hundreds – comprising the
plausible drug combinations for a patient at a given time point. (3)
Selecting an appropriate therapy based on the molecular characterization
of the patient is so difficult that it clearly requires computer support.
By examining other diseases we find that therapy of malignant tumors is
developing into a discipline where diagnostics are based on detailed
genomic, transcriptomic, proteomic and possibly metabolomics profiling
of the patient, thus characterizing each patient, practically individually. By
contrast, the number of therapy options – while still quite limited today –
is rising, as new drugs are being developed to treat many tumors and
combination drug therapies are becoming more and more popular [53].
For many other diseases, the number of therapy options is still limited and
informative biomarkers that characterize a disease state quantitatively
are being researched.
The fact is, HIV fulfills both characteristics of a spearhead: It is small and
pointed, manifested by the small size of the HIV genome and the
comparative simplicity of the viral mechanisms for resistance. At the
same time, the spearhead is at the front of the spear, symbolizing the
advanced state of HIV therapy over that of other diseases, concerning the
structural characteristics of personalized medicine.viral strains, each of which covers at least 15–20% of the
whole viral population inside the patient’s blood. Variants
are represented by multiple amino acids in certain sequence
positions. Thus, Sanger sequencing offers only a very rough
representation of the viral population and can miss impor-
tant, if small, resistant minorities. This is especially crucial in
viral tropism testing (see Box 1), where a small minority of so-
called X4-viruses can cause the therapy with a CCR5 blocker
to fail. There are two approaches to overcome this problem.
The first is to provide clinical correlates to the prediction
server providing information on the patient’s immune status.
For instance, a low CD4 T-cell count reflects a compromised
immune system, which is correlated with a higher probability
of emerging X4-viruses, even if such viruses cannot be
detected by Sanger sequencing [19]. The second is to base
the prediction on next generation sequencing (NGS) data
[20]. The geno2pheno[454] server offers this type of analysis
for genotypic tropism testing [21]. Minor viral populations
are found with much higher confidence using NGS data. NGS
data can be of special value even if they are only available in a
research setting – for training the bioinformatical prediction
model – and not in the clinical test scenario. Specifically,
when used for predictions based on Sanger data, models
trained on NGS data can outperform models trained on
Sanger data [22].
The genotypic resistance test based on viral RNA from
circulating virus particles is confounded by technical problems
caused by a low viral load. Therefore, resistance analysis based60 www.drugdiscoverytoday.comon proviral DNA has become a focus of attention. Tropism
determination from proviral DNA has already been incorpo-
rated into the daily diagnostic routine [23]. Resistance testing
based on proviral DNA – in addition to viral RNA – is still under
discussion [24,25], with the effectiveness of the approach for
therapy-naı¨ve patients gaining increasing support. For ther-
apy-experienced patients, a scenario appears promising that
assesses viral resistance based on a combination of viral and
proviral DNA combined with an inspection of the therapy
history of the patient (Box 2).
In summary, it can be stated that the use of virtual phe-
notypes has entered clinical routine, to the benefit of HIV
infected patients.
Therapy prediction engines
A virtual phenotype is an estimate of the outcome of a
laboratory experiment, which – in a second manual step –
is the basis for selection of an appropriate therapy. Therapy
prediction engines aim at automating this second step. They
Vol. 11, 2014 Drug Discovery Today: Technologies | Drug resistancerank different therapy options with respect to their likelihood
of success for a given patient. Therapy prediction engines
solve a much more challenging problem than virtual pheno-
types, because they aim at predicting clinical outcome rather
than just a laboratory readout. The care taker then selects a
suitable therapy from among the top ranking therapies
returned by the prediction engine. In doing so, she will take
patient parameters into account that are not considered by
the prediction engine – such as side effects and ease-of-use.
The first therapy prediction engines composed resistance
scores that were returned by the virtual phenotypes in a
relatively simplistic manner. Examples include the genotypic
susceptibility score (GSS), which is a normalized sum of the
resistance scores of the virus against drugs from different
classes [26]. More advanced systems employ state-of-the-art
statistical learning methods to supply a prediction that
includes both the estimated viral resistance and additional
information, such as interactions between drugs and an
estimate of the expected evolutionary development of the
virus to escape therapy in the future.
Studies evaluating new approaches to predict therapy out-
come usually precede the development of therapy prediction
engines. Several recent studies on this subject point in
interesting directions for future therapy prediction. One of
them is a model for predicting therapy outcome that incor-
porates drug properties, fitness differences between suscep-
tible and resistant strains, mutations, and adherence [27].
However, this method is still of limited use for clinical
purposes due to various simplifications (e.g., the study only
considers single-point mutations). A study in which evolu-
tionary escape dynamics of HIV was modeled to account for
several resistance mutations was able to show good agree-
ment between the estimated individualized genetic barrier
to a regimen and therapeutic outcome [28]. Additionally, the
potential of incorporating cross-resistance information was
evaluated [29].
Therapy prediction systems can use the estimates provided
by virtual phenotypes for their prediction of therapy efficacy
and, in addition, they can utilize a variety of additional
information on the patient, including clinical correlates,
information on patient history – such as previously applied
drugs or drug combinations and previously observed resis-
tance mutations – and even information on patient geno-
types – such as HLA alleles. Several therapy prediction
systems have been reported and are available on the Internet
(THEO from the geno2pheno suite [30], the EuResist predic-
tion engine [31], and the RDI TREPS system [32]). Various
forms of communicating information on patient history to
the prediction system have been explored [32–35]. Also,
current prediction systems do not utilize HLA information,
even though it is well documented that HIV adapts to HLA
class I and HLA class II presentation in therapy-naı¨ve patients
[36,37]. Furthermore, there are also positions that are underpressure by both HLA presentation and specific antiretroviral
drugs [38].
Specifically to cater to the needs of the low and middle
income countries (LMICs), prediction systems have been
developed that assess the efficacy of a therapy without access
to sequence information on the viral genome [39,40]. In this
case, information on previously applied therapies and the
viral load are used as a proxy for the genome sequence. This is
plausible, as every applied therapy leaves its fingerprint in the
viral genome in the form of resistance mutations. Such
systems are useful for therapy selection in LMICs but, as it
is to be expected, the performance of such systems does not
reach the level of the performance of systems utilizing the
genome sequence. Also, the viral load is not routinely mon-
itored in most developing countries, although this is
expected to change in the future.
Therapy prediction engines are the subject of intensive
research. A limited retrospective study comparing compu-
ter-based prediction with expert-crafted therapies has been
performed on the EuResist engine [41]. However, in contrast
to virtual phenotypes, the use of therapy prediction engines
has not yet entered clinical routine. There are several putative
reasons for this. One is validation. To this day, there is no
established benchmark on which to compare the perfor-
mances of such systems in an unbiased scenario. Such a
benchmark would necessitate the general availability of the
respective data set and agreement on definitions of therapy
success. The field has not matured to that state. A second
reason is most probably that, in contrast to virtual pheno-
types, today’s therapy prediction engines are less interpreta-
ble. The prediction is usually the response of a multivariate
statistical model in a high-dimensional data space. Making
predictions plausible to medical users is a task that is not
sufficiently addressed by today’s therapy prediction engines.
Current research on therapy prediction engines is directed at
these issues.
Validation, regulation, and certification of in silico prediction
systems
Thankfully, and probably due to the high need for effective
HIV therapies, virtual phenotypes have entered clinical rou-
tine. The certification of computer-based systems, especially of
the use of therapy prediction engines, meets with methodical
problems, however. Certification has only been carried out for
assay systems or laboratory services that entail the software as a
component. In the first case, the laboratory device is certified
(Siemens TruGene1, Abbot ViroSeq1), and in the second the
respective lab receives the certification. Prospective studies on
the performance of the software itself have not been carried
out. Current use of the systems is supported by retrospective
studies [13,41–44]. To this day, the classical design of a pro-
spective study with a limited number of (mostly two or three)
arms and mostly univariate power analysis has not been fullywww.drugdiscoverytoday.com 61
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has to incorporate a multitude of therapy options with the
resulting small patient groups for each option. The issue of
dealing with complex biomarkers has been investigated most
in the context of cancer [45,46]. Contributions targeted to HIV
therapy address the certification of new drugs [47] but also the
therapy selection problem [48]. The problem of designing
suitable prospective clinical studies in this context has been
recognized for some time. Open challenges are presented by
the fact that power analyses have been developed for only few
multivariate statistical models, see, for example, [49,50].
Furthermore, certification procedures have to be adapted to
a setting, where the statistical model that supports therapy
selection can be refined in an iterative retraining process, as
new data are being collected and without the need to go
through complete certification at every update.
Conclusions
Computer-assisted HIV therapy is a spearhead of personalized
medicine. It is characterized by the utilization of complex
genomic biomarkers – relevant regions of the viral genome –
and a multitude of therapy options. The therapy selection
problem is governed by viral resistance and is hard, or even
impossible to perform manually. There are two generations of
systems that support therapy selection. The first generation –
virtual phenotypes – predicts the resistance of the virus against
any individual drug in the arsenal. Virtual phenotypes have
entered clinical routine. The second generation – therapy
prediction engines – performs a fusion of diverse information
on a patient, including resistance estimates, information on
patient history and clinical correlates. Therapy prediction
engines predict the likelihood of therapy success and are the
object of intense study. To date, they are used in research
settings but they have not yet entered clinical routine.
Table S1, provided in the supplement, lists virtual pheno-
types and therapy prediction systems in more wide-spread use,
some for research purposes and some even in clinical routine.
We envision the further development of computer-based
resistance analysis of HIV going in the following directions.
(1) Therapy prediction engines will be further developed and
made more interpretable. Their predictive power will increase
both by refining the statistical learning technology and by
supplying additional information on the patient that may
impact their therapy outcome. (2) The currently prevalent
technology of Sanger sequencing will be replaced by next
generation sequencing. This will afford a higher resolution of
the viral population, resulting in a higher sensitivity in
detecting resistant viral minorities, and facilitate the analysis
of larger genome parts of HIV, ideally the full HIV genome at
reasonable cost. Using this technology, one may also resolve
the current problem of increased observed phenotypic resis-
tance without a genotypic fingerprint visible in Sanger data of
the genomic regions routinely monitored, so far [51,52].62 www.drugdiscoverytoday.comThe technology that has been successful for HIV therapy
can also work for other infectious diseases. For the HCV
infection, which causes hepatitis C and hepatocellular carci-
noma, there is a rapidly growing arsenal of antiviral drugs
under development, and combination drug therapies will
become routine in the next few years. The geno2pheno server
already offers a rules-based virtual phenotype of HCV drug
resistance. With mounting data on phenotypic resistance we
are prepared to supply a statistical model of drug resistance on
that server. However it is unclear, whether such an offer is as
essential for HCV as for HIV. There is the hope that, with
highly effective combination drug therapies against HCV, the
patient can be cleared of the virus in a limited amount of
time. This may limit the need for computer-assisted therapy
selection – as in tuberculosis, where simple tabular rules for
administering drugs suffice. The HBV infection that causes
hepatitis B is another case for which this technology may be
of use, but its significance is not yet clear.
We see major potential for applying this technology to
fight cancer in the future. The situation for cancer is much
like that of an HIV infection: We have a parasitic genome that
takes over control of the cell, evolves rapidly and escapes to
resistant variants when confronted with drug therapy. In the
case of cancer, the parasitic genome is that of the tumor cell.
In contrast to HIV, both the genome and the mechanisms for
developing resistance are much more complex and diverse.
One thing shared by both scenarios is the complication due
to the heterogeneity of the population of parasitic genomes.
The parallels between HIV and cancer in this respect are
further explored in [53].
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